Combination therapy with bevacizumab and a CCR2 inhibitor for human ovarian cancer: An in vivo validation study

BACKGROUND: Anti‐angiogenic therapy with bevacizumab (BEV), an anti‐VEGF antibody, plays a critical role in the treatment of ovarian cancer. However, despite an encouraging initial response, most tumors become resistant to BEV over time, and a new strategy that enables sustainable treatment using BE...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhai, Tianyue, Mitamura, Takashi, Wang, Lei, Kubota, Shimpei I., Murakami, Masaaki, Tanaka, Shinya, Watari, Hidemichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166889/
https://www.ncbi.nlm.nih.gov/pubmed/36810973
http://dx.doi.org/10.1002/cam4.5674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166889/
https://www.ncbi.nlm.nih.gov/pubmed/36810973
http://dx.doi.org/10.1002/cam4.5674

Ejemplares similares